Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Antineoplastic combined drug, and applications thereof in preparation of anticancer drugs

An anti-cancer drug and anti-tumor technology, applied in the field of biomedicine, can solve the problems of poor selectivity, drug resistance, toxic and side effects, etc.

Inactive Publication Date: 2017-12-08
SICHUAN JIUZHANG BIO TECH CO LTD
View PDF2 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The technical scheme of the present invention can solve the defects of poor selectivity of drugs targeting EGFR, various toxic and side effects, and drug resistance, improve the targeting of drugs targeting EGFR, reduce toxic and side effects, and reverse Its resistance, improve patient compliance

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antineoplastic combined drug, and applications thereof in preparation of anticancer drugs
  • Antineoplastic combined drug, and applications thereof in preparation of anticancer drugs
  • Antineoplastic combined drug, and applications thereof in preparation of anticancer drugs

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0036] Example 1 Effects of Medication Alone and Combined Medication on Different Normal Cell Lines

[0037] 1.1 Materials and Instruments

[0038] Test drugs: chlorogenic acid, erlotinib, gefitinib, icotinib, afatinib, trastuzumab, lapatinib, nimotuzumab, cetuximab .

[0039] Tested cell lines: human lung cancer cell line A549, human breast cancer cell line MDA-MB-453, human nasopharyngeal carcinoma cell line CNE-1, human normal lung epithelial cell BEAS-2B, human normal breast cell MCF10A, human normal nasal cavity Epithelial cells RPMI2650.

[0040] 1.2 Experimental method

[0041] Take a bottle of cells in the logarithmic growth phase, wash them twice with PBS, digest with 0.25% trypsin, and prepare a single cell suspension with RPMI-1640 culture medium containing 10% calf serum for counting. Inoculate in a 96-well culture plate under sterile conditions, and the number of inoculated cells is 5×l0 3 / hole. cells at 37°C, 5% CO 2 After incubation for 24 h in the incub...

Embodiment 2

[0066] Example 2 Chlorogenic acid reverses the drug resistance of human lung adenocarcinoma cell PC9 to gefitinib in vitro

[0067] 2.1 Materials and Instruments

[0068] Test drug: chlorogenic acid; gefitinib

[0069] Tested cell lines: PC9 cells, PC9 / ZD is a self-screening gefitinib-resistant cell line

[0070] 2.2 Experimental method

[0071] 2.2.1 Cultivation of drug-resistant cell lines

[0072] Human lung adenocarcinoma cell line PC9 cells were exposed to gefitinib (200nmol / L) for up to 3 months, and the gefitinib-resistant cell clones were selected to become PC9 / ZD cell lines. These two kinds of cells respectively have the ability of stable drug resistance to gefitinib. PC9 cells and PC9 / ZD cells were grown on the wall at 25cm 2 Culture flasks were cultured in DMEM medium containing 10% fetal bovine serum in 5% CO 2 , and incubated in a 37°C incubator. Observe the cells every day. When the cells grow to cover 70%-80% of the bottom of the bottle, they are subcultu...

Embodiment 3

[0089] Example 3 Synergistic and attenuating effects of chlorogenic acid and EGFR-targeted drug combination on tumor inhibition in vivo

[0090] 3.1 Materials and Instruments

[0091] Test drug: chlorogenic acid; afatinib, erlotinib, panitumumab, nimotuzumab

[0092] Tested cell lines: G422 cells, Lewis mouse lung cancer cell lines

[0093] Test animals: BABLc mice, C57BL / 6 mice

[0094] 3.2 Experimental method

[0095] 3.2.1 Establishment of experimental animal tumor models

[0096] Collect the cells in the logarithmic growth phase, centrifuge at 1000rpm for 5min, wash the cell sediment twice with PBS, and adjust the cell concentration to 1x10 with serum-free medium after counting 7 / m1, sent to the animal room under sterile conditions. Under sterile experimental conditions, mice were subcutaneously injected with 1x10 7 / m1 cells, 0.1ml per mouse, obvious skin mounds appeared in the injection area, and large rice grain nodules appeared in the left armpit of the nude mic...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an antineoplastic combined drug, and applications thereof in preparation of anticancer drugs. The antineoplastic combined drug comprises, by weight, 10 to 40 parts of a first reagent and 2 to 40 parts of a second reagent. The invention also discloses applications of chlorogenic acid in preparing anticancer drug toxic and side effect inhibitors. EGFR is taken as the target point of the anticancer drugs. According to the applications, the targeting performance of the anticancer drugs in treatment of non-small cell carcinoma, breast cancer, malignant gliomas, and nasopharyngeal carcinoma is improved, the toxic and side effect is reduced, and generation resistance on the drugs taking EGFR as the target point is delayed.

Description

technical field [0001] The invention relates to the field of biomedicine, in particular to an anti-tumor combined drug and its use in preparing anti-cancer drugs. Background technique [0002] Chlorogenic acid is a carboxyphenolic acid composed of caffeic acid and quinic acid. Chlorogenic acid has a wide range of pharmacological effects, including biological activities such as anti-oxidation, anti-bacterial and anti-inflammatory, tumor inhibition, liver protection and gallbladder, blood circulation and blood pressure reduction. [0003] EGFR (Epidermal Growth Factor Receptor) (erbB-1 / HER1) is a member of the HER family, the other three members are: erbB-2 (HER2 / neu), erbB-3 (HER3) and erbB-4 (HER4 ). EGFR is a receptor tyrosine kinase (RTK), which is overexpressed or abnormally expressed in various tumors such as non-small cell lung cancer, breast cancer, colorectal cancer, head and neck cancer, gastric cancer, ovarian cancer, and pancreatic cancer. The occurrence and dev...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/216A61K45/00A61P35/00A61K31/5377A61K31/517A61K39/395
CPCA61K31/216A61K31/517A61K31/5377A61K39/39566A61K45/00
Inventor 张洁黄望杨华蓉张梦甜
Owner SICHUAN JIUZHANG BIO TECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com